Amgen Inc. (NASDAQ:AMGN) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have been assigned an average rating of “Hold” from the thirty-three analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $425.69.

A number of brokerages have recently issued reports on AMGN. Barclays increased their price target on shares of Amgen from $400.00 to $430.00 and gave the company an “equal weight” rating in a report on Monday. Sanford C. Bernstein boosted their price objective on shares of Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. raised their price objective on Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Argus lifted their price target on Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research note on Thursday, November 12th.

Check Out Our Latest Research Report on Amgen

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Raffa Wealth Management LLC acquired a new position in shares of Amgen in the third quarter worth $200,000. Doheny Asset Management CA lifted its position in shares of Amgen by 2.4% in the third quarter. Doheny Asset Management CA now owns 1,245 shares of the medical research company’s stock valued at $525,000 after acquiring an additional 29 shares in the last quarter. WCG Wealth Advisors LLC boosted its stake in shares of Amgen by 7.4% during the third quarter. WCG Wealth Advisors LLC now owns 14,189 shares of the medical research company’s stock valued at $5,981,000 after acquiring an additional 981 shares during the last quarter. PYA Waltman Capital LLC boosted its stake in shares of Amgen by 14.2% during the third quarter. PYA Waltman Capital LLC now owns 20,257 shares of the medical research company’s stock valued at $8,539,000 after acquiring an additional 2,522 shares during the last quarter. Finally, Keel Point LLC increased its position in Amgen by 31.6% during the 3rd quarter. Keel Point LLC now owns 2,901 shares of the medical research company’s stock worth $1,223,000 after purchasing an additional 697 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7%

NASDAQ:AMGN opened at $462.32 on Thursday. The stock has a fifty day moving average price of $425.81 and a two-hundred day moving average price of $381.77. The stock has a market capitalization of $250.07 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 3.25 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen has a 1 year low of $312.39 and a 1 year high of $483.99.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $5.64 earnings per share. As a group, sell-side analysts anticipate that Amgen will post 23.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

Amgen Company Profile

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Stories

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.